TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer.
Saved in:
| Title: | TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer. |
|---|---|
| Authors: | Kumar V; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Yochum ZA; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA., Devadassan P; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Huang EH; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Miller E; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Baruwal R; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Rumde PH; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., GaitherDavis AL; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Stabile LP; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Burns TF; Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. burnstf@upmc.edu.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA. burnstf@upmc.edu.; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. burnstf@upmc.edu. |
| Source: | Oncogene [Oncogene] 2024 May; Vol. 43 (19), pp. 1431-1444. Date of Electronic Publication: 2024 Mar 01. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
